BioMarin's (BMRN) Price Target Raised to $155 at RBC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
BioMarin (BMRN) PT Raised to $155 at UBS; Best Catalyst Path in Biotech
July 9, 2015 8:36 AM EDTUBS analyst Andrew Peters reiterated a Buy rating and boosted his price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) to $155.00 (from $136.00), saying it still has the best catalyst path in biotech.
"We are revising our BMRN model ahead of 2Q15 earnings and believe the stock continues to be well positioned ahead of the most robust catalyst path in biotech," Peters said. "Importantly, we have updated our model to reflect a more bullish outlook on BMN-111 in achondroplasia following positive data last month as well as an improved view on... More
